ReviewEmerging clinical setting of direct oral anticoagulants atherothrombotic events preventionDi Fusco, Stefania A.a; Lucà, Fabianab; Gulizia, Michele M.c; Gabrielli, Domenicod; Colivicchi, FurioaAuthor Information aCardiology Unit, Emergency Departement, San Filippo Neri Hospital, Rome bCardiology Department, Big Metropolitan Hospital, Reggio Calabria cCardiology Department, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specialità, Catania dCardiology Unit, Ospedale Civile Augusto Murri, Fermo, Italy Correspondence to Stefania A. Di Fusco, Cardiology Unit, San Filippo Neri Hospial, via Martinotti, 20, 00135 Rome, Italy E-mail: email@example.com Received 23 July, 2019 Accepted 5 October, 2019 Journal of Cardiovascular Medicine: January 2020 - Volume 21 - Issue 1 - p 1-5 doi: 10.2459/JCM.0000000000000894 Buy Metrics Abstract Despite substantial progress in the treatment of atherosclerotic disease a non-negligible rate of acute atherothrombotic events persists. Evidence suggesting a safer profile of direct oral anticoagulants (DOACs) compared with vitamin K antagonists and the involvement of coagulation in the atherosclerotic process has led to exploration of the role of DOACs in the prevention of atherothrombotic events. In this review, we discuss the findings of recent studies on DOACs, particularly rivaroxaban, in atherothrombotic disease which represents a new clinical setting for oral anticoagulants. © 2020 Italian Federation of Cardiology. All rights reserved.